Answers are grounded in this paper and cite their sources.
Abstract 3′-Sialyl-3-fucosyllactose (3′S3FL) is a representative fucose-containing sialylated human milk oligosaccharide with distinctive biological functions, but its in vitro synthesis is limited by the poor tolerance of α2,3-sialyltransferases toward fucosylated acceptors. Here, we report an engineered α2,3-sialyltransferase variant, R60V, with enhanced catalytic performance toward the 3-fucosyllactose (3-FL) substrate. R60V exhibited a 3.6-fold enhancement in transglycosylation activity and a nearly 5-fold lower apparent Km for 3-FL. Its half-life at 40 °C extended from 42.55 to 89.82 h. Mechanistic analyses revealed that R60V alleviated steric hindrance for 3-FL binding, promoted productive interactions with the catalytic residue, and balanced local flexibility with global stability. Furthermore, a one-pot cascade system comprising R60V and a CMP-sialic acid synthetase was established, enabling in situ sialyl donor generation and affording 9.31 mM 3′S3FL in 93.13% yield within 3 h under optimized conditions. This study provides a practical biocatalytic cascade platform for efficient 3′S3FL production.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: